Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Oral Treprostinil for the Treatment of Pulmonary Arterial Hypertension in Patients on Background Endothelin Receptor Antagonist and/or Phosphodiesterase Type 5 Inhibitor Therapy (The FREEDOM-C Study): A Randomized Controlled Trial

Autor: Tapson VF, Torres F, Kermeen F, Keogh AM, Allen RP, Frantz RP, Badesch DB, Frost AE, Shapiro SM, Laliberte K, Sigman J, Arneson C, GALIE', NAZZARENO

Background: Infused and inhaled treprostinil are effective for treatment of pulmonary arterial hypertension (PAH), although their administration routes have limitations. This study assessed the efficacy and safety of bid oral sustained-release trepro

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______4094::5ee3d8bd6d2eb040fa9b347f58ae3248
http://hdl.handle.net/11585/120319

Riociguat for the treatment of pulmonary arterial hypertension

Autor: Ghofrani, Ha, Galiè, N, Grimminger, F, Grünig, E, Humbert, M, Jing, Zc, Keogh, Am, Langleben, D, Kilama, Mo, Fritsch, A, Neuser, D, Rubin, Lj, 1 Study Group including Bortman G, Patent, Keogh, A, Kermeen, F, Feenstra, J, Williams, T, Reeves, G, Kilpatrick, D, Lang, I, Kahler, C, Mascherbauer Steringer, R, Vachiery, Jl, Delcroix, M, Meyer, G, Arakaki, J, Santana, M, Waetge, D, Granton, J, Helmersen, D, He, J, Jing, Z, Zhou, D, Huang, Y, Wang, C, Jansa, P, Neilsen Kudsk JE, Hachulla, E, De Groote, P, Frachon, I, Bourdin, A, Pison, C, Bauer, F, Dromer, C, Marquette, Ch, Degano, B, Neurohr, C, Wilkens, H, Hoffken, G, Hoeper, M, Ghofrani, A, Wirtz, H, Rosenkranz, S, Ewert, R, Orfanos, S, Kramer, M, Ben Gal, T, Scelsi, L, Vizza, C, Harari, S, Confalonieri, M, Albera, Carlo, Fukumoto, Y, Sano, M, Hatano, M, Saji, T, Tanaka, S, Takeda, Y, Takehara, K, Matsubara, H, Kihara, Y, Shiohira, Y, Kawai, H, Homma, S, Satoh, T, Tokunaga, T, Ishizaki, T, Diaz, C, Zamudio, T, De Los Rios, M, Estupian, S, Cacho, Jr, Gamba, M, Beckert, L, Torbicki, A, Castro, G, Reis, A, Agapito, A, Martins, S, Kim, H, Lee, S, Chang, H, Song, Y, Chazova, I, Moiseeva, O, Lim, S, Yip, J, Barbera, J, Roman, A, Palma Jdel, C, Reitan, O, Soderberg, S, Jansson, K, Speich, R, Hsu, Hh, Lin, Hy, Cheng, Cc, Phrommintikul, A, Jaimchariyatam, N, Sayin, T, Kultursay, H, Ongen, G, Pepke Zaba, J, Coghlan, G, Peacock, A, Gibbs, J, Wagoner, L, Badesch, D, Frost, A, Hill, N, Allen, R, Waxman, A, Sood, N, Torres, F, Minai, O, Shapiro, S, Klinger, J, Engel, P, Garcia, H, Schuller, D, Poch, D, Rosenzweig, E, Mcconnell, J, Rischard, F, Olschewski, H, Haverkamp, W, Lehmacher, W, Hoischen, S, Collamati, S, Dehay, J, Hallmann, M, Menezes, F.

Riociguat, a soluble guanylate cyclase stimulator, has been shown in a phase 2 trial to be beneficial in the treatment of pulmonary arterial hypertension. METHODS: In this phase 3, double-blind study, we randomly assigned 443 patients with symptomati

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08a8fd42189d6ac9c1d50e70aff46618
http://hdl.handle.net/2318/152936

Molecular and functional analysis identifies ALK-1 as the predominant cause of pulmonary hypertension related to hereditary haemorrhagic telangiectasia

Autor: Harrison, R. E., Flanagan, J. A., Sankelo, M., Abdalla, S. A., Rowell, J., Rajiv David Machado, Elliott, C. G., Robbins, I. M., Olschewski, H., Mclaughlin, V., Gruenig, E., Kermeen, F., Laitinen, T., Morrell, N. W., Halme, M., Räisänen-Sakolowski, Trembath, R. C.

Publikováno v: Scopus-Elsevier

BACKGROUND Mutations of the transforming growth factor beta (TGFbeta) receptor components ENDOGLIN and ALK-1 cause the autosomal dominant vascular disorder hereditary haemorrhagic telangiectasia (HHT). Heterozygous mutations of the type II receptor B

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::8f50c78bcad4e264e650095fc382aa83
http://digitallibrary.ihi.or.tz/272/

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.